The estimated Net Worth of Burt A Adelman is at least $2.36 Milione dollars as of 15 October 2007. Burt Adelman owns over 60,500 units of Astria Therapeutics Inc stock worth over $625,717 and over the last 21 years he sold CATB stock worth over $1,664,256. In addition, he makes $74,900 as Independent Director at Astria Therapeutics Inc.
Sign up
Burt Adelman CATB stock SEC Form 4 insiders trading
Burt has made over 23 trades of the Astria Therapeutics Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 60,500 units of CATB stock worth $3,966,380 on 15 October 2007.
The largest trade he's ever made was exercising 144,000 units of Astria Therapeutics Inc stock on 25 July 2007 worth over $6,897,600. On average, Burt trades about 18,101 units every 40 days since 2003. As of 15 October 2007 he still owns at least 73,269 units of Astria Therapeutics Inc stock.
You can see the complete history of Burt Adelman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Burt Adelman biography
Dr. Burt A. Adelman M.D. serves as Independent Director of the Company. Dr. Adelman has served as a Senior Advisor at Novo Ventures US Inc., a venture capital firm, since September 2017. Previously, Dr. Adelman was Executive Vice President, Research and Development and Chief Medical Officer of Dyax, a biotechnology company, from February 2012 until its acquisition by Shire in January 2016. Prior to joining Dyax, he worked at Eleven Biotherapeutics, a biotechnology company, where he served as interim President of Research and Development from 2010 to 2011 and as Senior Advisor from February 2011 until December 2011. From 1991 to 2007, Dr. Adelman held positions of increasing responsibility at Biogen, a global biotechnology company, ultimately as Executive Vice President, Portfolio Strategy. From 1998 through 2020, Dr. Adelman served as a lecturer in medicine at Harvard Medical School and as an Associate Physician at Brigham and Women's Hospital. Dr. Adelman holds an M.D. from Cornell Medical College and a B.S. in biology from Trinity College. He completed residency training and a hematology fellowship at the Peter Bent Brigham Hospital. Adelman is qualified to serve on our Board of Directors because of his broad experience in drug development.
What is the salary of Burt Adelman?
As the Independent Director of Astria Therapeutics Inc, the total compensation of Burt Adelman at Astria Therapeutics Inc is $74,900. There are 6 executives at Astria Therapeutics Inc getting paid more, with Jill Milne having the highest compensation of $1,032,800.
How old is Burt Adelman?
Burt Adelman is 67, he's been the Independent Director of Astria Therapeutics Inc since 2016. There are 2 older and 8 younger executives at Astria Therapeutics Inc. The oldest executive at Astria Therapeutics Inc is Michael Kishbauch, 71, who is the Independent Director.
What's Burt Adelman's mailing address?
Burt's mailing address filed with the SEC is C/O CATABASIS PHARMACEUTICALS, INC.,, 100 HIGH STREET, FLOOR 28, BOSTON, MA, 02110.
Insiders trading at Astria Therapeutics Inc
Over the last 9 years, insiders at Astria Therapeutics Inc have traded over $0 worth of Astria Therapeutics Inc stock and bought 3,064,797 units worth $36,777,564 . The most active insiders traders include Jean George, Nicholas Galakatos e Lifesciences Ii, L.P.Clarus.... On average, Astria Therapeutics Inc executives and independent directors trade stock every 0 days with the average trade being worth of $2,617,339. The most recent stock trade was executed by Lifesciences Ii, L.P.Clarus... on 30 June 2015, trading 376,695 units of CATB stock currently worth $4,520,340.
What does Astria Therapeutics Inc's logo look like?
Complete history of Burt Adelman stock trades at Biogen Inc e Astria Therapeutics Inc
Astria Therapeutics Inc executives and stock owners
Astria Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jill Milne,
President, Chief Executive Officer, Co-Founder, Director -
Joanne Donovan,
Chief Medical Officer -
Andrew Nichols,
Chief Scientific Officer -
Kenneth Bate,
Independent Chairman of the Board -
Michael Kishbauch,
Independent Director -
Gregg Lapointe,
Independent Director -
Burt Adelman,
Independent Director -
Hugh Cole,
Independent Director -
Joanne Beck,
Independent Director -
Andrew Komjathy,
Chief Commercial Officer -
Benjamin Harshbarger,
Senior Vice President, General Counsel -
Noah Clauser,
Chief Financial Officer -
Andrea Matthews,
IR Contact Officer -
Rick Modi,
Chief Business Officer -
Jean George,
Director -
V, Llcsv Life Sciences Fund...,
-
Ron Laufer,
Director -
Michael Jay Ross,
Director -
Michael Jirousek,
Chief Scientific Officer -
Lifesciences Ii, L.P.Clarus...,
-
Ian C. Sanderson,
Chief Financial Officer -
Ventures, Inc. Med Immune,
10% owner -
Nicholas Galakatos,
Director -
Edward K. Hibben,
Chief Business Officer -
Fred Callori,
Director -
Jonathan Violin,
Director -
Deirdre A. Cunnane,
Chief Legal Officer -
Advisors Llcperceptive Life...,